JP7605739B2 - 百日咳ブースターワクチン - Google Patents

百日咳ブースターワクチン Download PDF

Info

Publication number
JP7605739B2
JP7605739B2 JP2021531950A JP2021531950A JP7605739B2 JP 7605739 B2 JP7605739 B2 JP 7605739B2 JP 2021531950 A JP2021531950 A JP 2021531950A JP 2021531950 A JP2021531950 A JP 2021531950A JP 7605739 B2 JP7605739 B2 JP 7605739B2
Authority
JP
Japan
Prior art keywords
amount
vaccine
present
booster vaccine
booster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531950A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020117618A5 (enExample
JP2022511511A (ja
Inventor
ニコラ・ビュルダン
マルティナ・オクス
マリー・ギャリノ
マルティーヌ・シャボー－リウー
ナタリー・レヴェノー
ユアンチン・リウ
ノエル・ミストレッタ
Original Assignee
サノフィ パスツール インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール インコーポレイテッド filed Critical サノフィ パスツール インコーポレイテッド
Publication of JP2022511511A publication Critical patent/JP2022511511A/ja
Publication of JPWO2020117618A5 publication Critical patent/JPWO2020117618A5/ja
Priority to JP2024126656A priority Critical patent/JP2024156862A/ja
Application granted granted Critical
Publication of JP7605739B2 publication Critical patent/JP7605739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021531950A 2018-12-05 2019-11-29 百日咳ブースターワクチン Active JP7605739B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024126656A JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306621.6 2018-12-05
EP18306621 2018-12-05
PCT/US2019/063840 WO2020117618A1 (en) 2018-12-05 2019-11-29 Pertussis booster vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024126656A Division JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Publications (3)

Publication Number Publication Date
JP2022511511A JP2022511511A (ja) 2022-01-31
JPWO2020117618A5 JPWO2020117618A5 (enExample) 2022-11-09
JP7605739B2 true JP7605739B2 (ja) 2024-12-24

Family

ID=65628487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531950A Active JP7605739B2 (ja) 2018-12-05 2019-11-29 百日咳ブースターワクチン
JP2024126656A Pending JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024126656A Pending JP2024156862A (ja) 2018-12-05 2024-08-02 百日咳ブースターワクチン

Country Status (6)

Country Link
US (1) US20220054615A1 (enExample)
EP (1) EP3890770A4 (enExample)
JP (2) JP7605739B2 (enExample)
CN (1) CN113395977A (enExample)
TW (1) TWI877126B (enExample)
WO (1) WO2020117618A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021183533A1 (en) * 2020-03-09 2021-09-16 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509522A (ja) 2012-03-08 2015-03-30 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013301312A1 (en) * 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US9526776B2 (en) * 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2016203025A1 (en) * 2015-06-17 2016-12-22 Curevac Ag Vaccine composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509522A (ja) 2012-03-08 2015-03-30 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン

Also Published As

Publication number Publication date
TWI877126B (zh) 2025-03-21
EP3890770A4 (en) 2022-09-28
WO2020117618A1 (en) 2020-06-11
CN113395977A (zh) 2021-09-14
EP3890770A1 (en) 2021-10-13
JP2022511511A (ja) 2022-01-31
JP2024156862A (ja) 2024-11-06
TW202038991A (zh) 2020-11-01
US20220054615A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
Ellis New technologies for making vaccines
Brennan et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus
JP2024156862A (ja) 百日咳ブースターワクチン
McCluskie et al. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants
Ellis Technologies for the design, discovery, formulation and administration of vaccines
US11744884B2 (en) Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
KR102041032B1 (ko) 돼지 생식기 호흡기 증후군 및 돼지 써코바이러스 연관 질환에 대한 백신 조성물
JPH04502402A (ja) 組み換えフラジエリンのワクチン
WO2021158440A1 (en) Immunogenic compositions to treat and prevent microbial infections
JP2021181445A (ja) 多価ワクチン組成物
AU2020358775B2 (en) Immunogenic compositions
McCLUSKIE et al. Immunization against hepatitis B virus by mucosal administration of antigen–antibody complexes
KR101832610B1 (ko) 돼지 유행성 설사 바이러스 유래 수용성 재조합 항원 단백질 및 이를 포함하는 돼지 유행성 설사 예방 또는 치료용 백신 조성물
Fooladi et al. Cellular immunity survey against urinary tract infection using pVAX/fimH cassette with mammalian and wild type codon usage as a DNA vaccine
JP6401148B2 (ja) 抗原および抗原の組み合わせ
Olszewska et al. Nasal delivery of epitope based vaccines
US20090087456A1 (en) Adjuvanted vaccine
CN113226361A (zh) 疫苗多肽组合物及方法
US20230104907A1 (en) Live salmonella typhi vectors engineered to express protein antigens and methods of use thereof
US20220118079A1 (en) Immunogenic Antigens
Chapartegui-González et al. Recent Progress in Shigella and Burkholderia pseudomallei Vaccines. Pathogens 2021, 10, 1353
Liew Biotechnology of vaccine development
Schild et al. Vaccines: Past, present and future
EA048463B1 (ru) Иммуногенные композиции
EA045050B1 (ru) Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241212

R150 Certificate of patent or registration of utility model

Ref document number: 7605739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150